Key points {#Sec1}
==========

Gadolinium-based contrast agent injection should be used cautiously in neuroimagingNon-contrast-enhanced MRI techniques can depict specific relevant physiological processesMRI diffusion, arterial spin labeling, spectroscopy, and amide proton transfer imaging are non-contrast-enhanced MRI techniques that can be used to answer specific clinical questions in neuroimaging

Background {#Sec2}
==========

Gadolinium-based contrast agents (GBCAs) in MRI were introduced in clinical practice in the 1980s to increase lesion detection and improve the disease characterization for many cerebral and vascular pathologies investigated with MRI \[[@CR1]\]. The effect of GBCAs in MRI is rendering a higher signal on T1-weighted images due to shortening of T1 relaxation time. In addition, GBCA was occasionally used for patients unsuitable for iodine-based contrast agent in CT examinations.

The use of GBCAs was initially considered safe without reported acute adverse events or long-term risks. However, after several reports on the association between nephrogenic systemic fibrosis and GBCA exposure in patients with renal impairment, some linear GBCAs were withdrawn from the market or their indication was restricted \[[@CR2]\]. More restrictive use of GBCAs in patients with renal impairment and the introduction of more stable non-linear GBCA chelates have lowered the incidence of nephrogenic systemic fibrosis \[[@CR3], [@CR4]\].

Recently, gadolinium deposition was been reported in the deep gray matter of the brain \[[@CR5], [@CR6]\] and in the bone \[[@CR7]\]. Neither of these reports demonstrated any association with clinical symptoms. Current recommendations of the use of GBCA in clinical practice and research now emphasize that GBCAs per standard practice should only be used when absolutely necessary and that GBCA can be used in research settings with appropriate guidance of protocols and ethical review board approval with informed patient consent \[[@CR5]\]. Furthermore, contrast enhancement adds to the cost of the MRI examination due to the cost of the additional scan time and of the contrast agent itself.

In the light of technological advances, additional costs, and possible long-term risks of GBCAs, the current role of GBCAs in neuroimaging can be discussed and re-evaluated. Only a limited number of studies have been designed to compare the diagnostic efficacy for non-contrast-enhanced MRI compared to contrast-enhanced techniques \[[@CR8]--[@CR10]\]. The aim of this paper is to review the potential use of non-contrast-enhanced MRI instead of contrast-enhanced MRI for specific diagnostic questions in neuroradiology. We describe the mechanism and limitations of GBCA contrast enhancement as well as the techniques that may serve as alternatives to GBCA contrast enhancement. Briefly, the topic of dynamic contrast-enhanced MRI is discussed. Then, we compare the diagnostic value and clinical applicability of non-contrast-enhanced with contrast-enhanced sequences in ten common diseases affecting the brain and report relevant statistical measures regarding diagnostic performance. Disease categories were ordered by the level of evidence for the ability of non-contrast-enhanced MRI to replace contrast-enhanced MRI in a clinical setting. The discussion gives a critical appraisal of the main findings.

Search strategy {#Sec3}
===============

Eligible articles were searched for in PubMed until September 2018. Search strings included a combination of the following search terms: MRI, MR, AUC (area under curve), sensitivity, specificity, diagnostic accuracy, performance, gadolinium, contrast, enhanced, and GBCA. Searches were conducted by two of the authors (AnFD, AlFD).

GBCAs and contrast enhancement {#Sec4}
==============================

It is unclear how GBCA is taken up and is eliminated from the brain \[[@CR11]\]. Tight junctions in the vessel endothelium and other specific mechanisms exclusive for the blood-brain barrier are supposed to prevent large molecules such as those in GBCAs to enter the brain \[[@CR12]\]. However, disease processes may break down the integrity of the blood-brain barrier, and these processes are predominantly inflammatory, infectious, or malignant \[[@CR13]\]. Hence, in such lesions, GBCAs will leak through the blood vessels and result in increased signal on T1-weighted images compared to normal unaffected brain. However, since several different disease processes disrupt the integrity of the tight junctions and lead to contrast enhancement, finding contrast enhancement on brain MRI is unspecific and can sometimes be misleading in clinical decision-making.

Limitations of static contrast enhancement in neuroimaging {#Sec5}
==========================================================

While contrast enhancement in neuroimaging is used clinically to increase sensitivity to detect an abnormality, the specificity is often lower. For example, static contrast enhancement alone cannot discriminate between which are low-grade and high-grade tumors in adults and children \[[@CR14], [@CR15]\], pseudoprogression and true intracranial tumor progression after radiation therapy \[[@CR16]\], and pseudoresponse and true response after anti-angiogenic or immunotherapy \[[@CR17]\]. Correct definition of the treatment response is important in order to select the optimal treatment for the patient and avoid premature cessation of an effective treatment \[[@CR17]\]. Further examples are discrimination between a ring-enhancing metastasis and glioblastoma \[[@CR18]\], or abscess, or indication of low tumor grade in vascularized oligodendroglial tumors \[[@CR19]\]. Another example is that contrast enhancement fails to detect tumor cells infiltrating beyond the contrast-enhancing lesion and into the surrounding white matter, like in high-grade gliomas \[[@CR20]\]. Further, the diffusion time of GBCA is not often considered in clinical practice, possibly hampering the detection of small lesions. Variable sensitivity of different T1-weighted sequences to the T1-shortening effects of GBCA is another reason for variable detectability.

As contrast enhancement per se is unspecific for disease categorization related to disruption of the blood-brain barrier, time-resolved MRI techniques using GBCAs have been developed \[[@CR21]\]. For example, MRI perfusion or perfusion-related techniques such as dynamic susceptibility contrast (DSC) and dynamic contrast-enhanced (DCE) MRI add specificity to contrast-enhanced MRI when assessing tumor grade and treatment-related changes. Non-contrast-enhanced MRI techniques that closely resemble these techniques are arterial spin labeling, time of flight, and phase-contrast MRI enabling perfusion estimation or vessel imaging.

Useful non-contrast-enhanced MRI techniques {#Sec6}
===========================================

While contrast-enhancement is important to increase signal to background for small lesions, depict an impaired blood-brain barrier, accentuate vessel structures, and estimate tissue perfusion, new non-contrast-enhanced MRI techniques must be able to offer reliable alternatives to answer these clinical questions. There are useful sequences without GBCA, which shall be introduced here.

Arterial spin labeling {#Sec7}
======================

Arterial spin labeling (ASL) is a non-contrast-enhanced technique that offers an estimation of brain perfusion such as cerebral blood flow (CBF) \[[@CR22], [@CR23]\]. Since the technique can depict tissue perfusion, it could replace GBCA-based MRI perfusion techniques such as dynamic susceptibility contrast (DSC) MRI and dynamic contrast-enhanced (DCE) MRI. In vessel imaging, ASL is often compared against digital subtraction angiography (DSA). With this technique, water protons (spins) in the blood are labeled magnetically by exposure to a radio-frequency pulse. These are then transported by the blood to the organ of interest and incorporated into the tissue by water exchange between blood and the tissue. Imaging is performed twice, once with (labeling acquisition) and once without the labeling (control acquisition). There are several variants of ASL pulse sequences. One variant is when the RF labeling is performed continuously (CASL) \[[@CR24]\] and another where the labeling is applied on a large volume with one or two short RF pulses (PASL) \[[@CR23]\]. A hybrid version of these two variants is the pseudocontinuous ASL (PCASL) where the continuous labeling pulse in CASL is replaced by a series of short pulses applied in the presence of a magnetic field gradient \[[@CR22]\]. This method is currently recommended in the white paper by Alsop et al. \[[@CR25]\]. For example, ASL has been tested for depicting arteriovenous malformations \[[@CR26]\] and in the response assessment of cerebral tumors \[[@CR27]\]. Main concerns with the technique include loss of signal due to susceptibility artifacts, motion artifacts, and low signal-to-noise ratio \[[@CR28]\].

Time of flight and phase-contrast MRI {#Sec8}
=====================================

Time of flight (TOF) MRI is a non-contrast-enhanced angiographic imaging method that measures and depicts the flow of blood inside a vessel compared to the surrounding static tissue \[[@CR29]\]**.** TOF images depict vessel structures in 2D and 3D and can be used both for arteries and veins. Hence, it is a method that could be used instead of contrast-enhanced MR angiography (MRA). In TOF imaging, T1 hyperintense lesions such as lipomas can be mistaken for a vascular structure such as an aneurysm, although fat-saturated images and an awareness of artifacts can help distinguish these conditions \[[@CR30]\]. Awareness should also be directed towards thrombus shine through in TOF MR arteriography and venography \[[@CR31]\]. Source images as well as T1-weighted images should be scrutinized in order to differentiate between high T1 signal in thrombosed areas and normal flow \[[@CR31]\].

Phase-contrast MRI is a non-contrast-enhanced sequence with a high rate of background suppression and excellent visualization of cerebral veins and high spatial resolution in 3D \[[@CR32]\]. In phase-contrast MR venography, only moving tissue contributes to the MRI signal and static tissue gives no signal \[[@CR32]\]. For example, TOF imaging can be of value when assessing for vessel patency in suspected occlusion or stenosis. Potential misinterpretations when assessing suspected dural sinus venous thrombosis can be related to sinus hypoplasia or atresia \[[@CR31]\]. Interpretation also requires awareness of normal sinus filling defects such as arachnoid granulations and intrasinus septations \[[@CR31]\].

Diffusion MRI {#Sec9}
=============

Diffusion MRI or diffusion-weighted imaging (DWI) is a method that depicts the diffusion of protons in the tissue. In DWI, tissues with hindered or restricted proton movement will appear bright with a low apparent diffusion coefficient (ADC). DWI hence offers a depiction of the tissue that contrast-enhanced techniques cannot offer. More advanced diffusion-weighted techniques will allow visualizing the movement of protons along white matter tracts or estimation of perfusion metrics that could offer a substitution to contrast-enhanced perfusion MRI.

Changes in tissue microstructure due to pathological conditions can be quantified by diffusion MRI. In its most basic form, diffusion MRI yields maps of the apparent diffusion coefficient (ADC). In white matter, the ADC is anisotropic and depends on the diffusion-encoding direction due to the organized structure of membranes in and around axons \[[@CR33]\]. This is the basis of diffusion tensor imaging and high angular resolution diffusion imaging (HARDI) methods for tractography \[[@CR34]\]. Methods that go beyond ADC quantification and diffusion tensor imaging include diffusion kurtosis imaging (DKI) \[[@CR35]\] and methods for microstructure imaging \[[@CR36]\]. Such methods offer a more detailed characterization of the tissue. With encoding strategies that go beyond the standard diffusion MR method, more advanced techniques could become more specific for quantification of tissue properties such as cell size, cell count, cell membrane permeability, or cell shapes \[[@CR36]\].

Diffusion MRI can also be used to acquire the perfusion fraction, which is related to the cerebral blood volume (CBV), by the so-called intravoxel incoherent motion imaging \[[@CR37], [@CR38]\]. Since perfusion imaging has shown to be a valuable tool in the medical investigations of, for example, stroke and tumors, intravoxel incoherent motion imaging is a potential diagnostic tool in these areas \[[@CR39]--[@CR42]\].

The main disadvantage of conventional DWI is that it is non-specific in terms of microstructure components, and observed values of the ADC can be affected by, for example, effects of flow apart from effects of diffusion \[[@CR43]\]. Further, reading a DWI image necessitates a concurrent evaluation of ADC and/or T2-weighted images to assess potential T2 shine-through \[[@CR43]\]. Finally, intravoxel incoherent motion (IVIM) perfusion estimates remain controversial and sensitive to echo time effects \[[@CR44]\].

Magnetic resonance spectroscopy {#Sec10}
===============================

MR spectroscopy (MRS) provides information about the chemical composition of the tissue \[[@CR45]\] and can be used for differential diagnosis and monitoring of treatment effects. It enables assessment of brain metabolism and can provide absolute metabolite concentrations, but in clinical practice, relative amounts (ratios) of different metabolites are usually reported \[[@CR46]\]. MRS does not provide images of the brain, but rather a spectrum reflecting the chemical composition of the tissue in the selected volumes of interest. Currently, no contrast-enhanced MRI technique can assess tissue properties as does MRS. Useful areas for MRS are tumor characterization and treatment assessment.

Obstacles related to the introduction of MRS into clinical practice are related to the lack of standardization in terms of data acquisition and post-processing \[[@CR47]\]. Other issues that also contribute to perceived difficulties with the technique include the placement of the MRS voxel, sensitivity for artifacts and motion, acquisition time, and post-processing of the data \[[@CR47], [@CR48]\].

Susceptibility weighted imaging {#Sec11}
===============================

Susceptibility weighted imaging (SWI) can be used to depict small areas in the brain causing inhomogeneity in the magnetic field rendering susceptibility artifacts. The possibility of depicting tiny structures with a high lesion-to-background signal is a potential advantage similar to that of contrast-enhanced T1-weighted images. Differences in magnetic susceptibility between deoxygenated and oxygenated blood render a phase difference between venous blood and surrounding tissue \[[@CR49]\]. This difference is exploited in susceptibility weighted imaging to depict cerebral venous structures \[[@CR49]\]. The method efficiently detects cerebral microbleeds, iron deposition, and cerebral calcifications \[[@CR50]\].

Main disadvantages with this technique are the artifacts produced from subject motion or dental implants \[[@CR51]\] as well as the sensitivity to blood oxygenation level \[[@CR52]\].

Amide proton transfer imaging {#Sec12}
=============================

Amide proton transfer (APT) imaging was developed as a new contrast to assess the tissue pH and protein content by MRI \[[@CR53]\]. Characterizing tissue properties based on pH and protein content could be an alternative to contrast-enhanced T1-weighted image depiction of impaired blood-brain barrier. The concept is based on the use of exchangeable protons to amplify the MR signal using a method called chemical exchange saturation transfer \[[@CR54]\]. In a process similar to ASL, but now just inside the tissue, these exchangeable protons are first labeled using RF and transferred to water protons through physical exchange \[[@CR55]\]. Fast repetition of this process leads to detection in MRI with sensitivity enhancements by factors of a hundred or more. This allows imaging of the signal from millimolar concentration of the exchangeable protons in these molecules with the molar sensitivity of water protons. Examples of groups containing these exchangeable protons are hydroxyls, amides, and amines. In APT-weighted (APTw) imaging, one uses the amide protons in mobile proteins and peptides in tissue as endogenous contrast. The signal intensity depends on the exchange rate between the amide and water protons and the number of amide protons. Therefore, two applications have been developed where one is sensitive to the change in exchange rate and the other depends on the protein concentration. One useful area for APT has been in brain tumor assessment. One disadvantage of APT in brain tumor imaging is the increased signal in proteinaceous cysts or hemorrhage that can be confounded with high-grade tumor if regular images are not carefully scrutinized for cystic or hemorrhagic tumor components \[[@CR56]\]. Concerns have also been raised about the presence of proteins leaking from the vascular bed in the setting of a brain metastasis causing increased APT in the perifocal edema of brain metastasis \[[@CR18]\].

Specific clinical applications of non-contrast-enhanced MRI {#Sec13}
===========================================================

Cerebrovascular disease {#Sec14}
-----------------------

### Stroke {#Sec15}

MRI is the most sensitive method to detect acute stroke \[[@CR57]\] and is often used for cases that are challenging to diagnose or in follow-up. Acute stroke imaging aims to detect treatable causes of stroke and exclude mimickers. Imaging must rule out bleeding, identify thrombus, and differentiate non-salvageable tissue (infarct core) from the penumbra, but should also strive to assess the collateral circulation. DWI can aid in predicting outcome after stroke in posterior circulation stroke \[[@CR58]\], and ASL-DWI mismatch has shown promise in identifying salvageable tissue in acute stroke \[[@CR59]\] with an AUC of 0.76. ASL and DWI 24 h after stroke can be used to predict functional outcome in acute stroke patients with an AUC of 0.85 \[[@CR60]\]. Further, susceptibility weighted imaging \[[@CR61]\] or TOF \[[@CR62]\] can be used to identify intraluminal thrombus or large vessel occlusion. However, a recent study shows that contrast-enhanced MRA shows higher accuracy (0.99) for detecting intracranial arterial occlusion compared to TOF (0.89) \[[@CR63]\]. In summary, non-contrast-enhanced MRI seems to be able to replace contrast-enhanced techniques in clinical practice.

### AVM and AV fistulas {#Sec16}

Vessel imaging can be used for non-contrast-enhanced evaluation of AVM, AV fistulas, aneurysms, and steno-occlusive diseases including moyamoya. Imaging evaluates the disease processes before and after therapy and identifies complications after therapy. Imaging must be able to delineate the lesion and assess feeding and draining vessels. Perfusion maps from ASL combined with susceptibility weighted imaging (AUC = 0.97) have shown to be superior to conventional MRI (AUC = 0.93) and equal to digital subtraction angiography (DSA) in the preoperative assessment of AVM \[[@CR64]\]. Further development of the ASL technique with super-selective ASL angiography shows a similar capacity as TOF to evaluate intracranial vessels and has shown promise in AVM evaluation \[[@CR65]\].

Perfusion maps from ASL have shown equal diagnostic performance to DSA in the assessment of shunting in AVM \[[@CR66]\] and to pre-therapeutically identify nidus, evaluating flow and AVM size reduction after therapy in a pediatric population \[[@CR26]\]. Post-therapeutic evaluation of AVMs by ASL has also been described \[[@CR67]\] with an AUC of 0.97. In a study evaluating ASL compared to DSA, results showed 100% sensitivity for ASL to evaluate AV-shunting and venous drainage in a pediatric population \[[@CR68]\].

ASL angiography has shown high diagnostic performance for the evaluation of AV fistulas with excellent conformity between 4D ASL MR angiography and DSA in the identification of the fistula site and the venous drainage with an agreement of 100% \[[@CR69]\], as quantified by the kappa value of 1.00 \[[@CR70]\]. The kappa value is an index describing the agreement between two raters, and a complete agreement is described by a kappa value of 1. Perfusion maps from ASL are highly accurate in determining AVM Borden type and detect cortical venous drainage \[[@CR71]\] with a sensitivity of 91% compared to DSA. Also, a 4D radial phase-contrast flow-tracking cartographic procedure showed good to excellent agreement between DSA and ASL \[[@CR72]\] with kappa values of 0.92--1.00.

Aiming to improve contrast-enhanced MRA, time-resolved contrast-enhanced MR angiography has been developed and tested in patients with AV fistulas with accurate delineation of the fistula architecture in seven out of eight patients \[[@CR73]\]. In summary, non-contrast-enhanced MRI seems to be able at least in part to replace contrast-enhanced techniques for vessel AV imaging.

### Aneurysm {#Sec17}

Pre-therapeutic imaging and post-therapeutic longitudinal follow-up must discern aneurysm size, location, and grade of occlusion. TOF MRA is the most widely used non-contrast-enhanced MR sequence for evaluation of cerebral aneurysms. Reports show that the performance of 3D TOF is equal to that of CT angiography \[[@CR74]\] with an AUC of 0.91 and comparable to contrast-enhanced MRA \[[@CR8]\] for assessing coiled aneurysms as occluded or patent. However, 3D TOF angiography showed more artifacts and lower detection rate of residual aneurysm patency compared with contrast-enhanced MR angiography \[[@CR8]\]. Pre-therapeutic 3D TOF MRA was comparably accurate in detecting aneurysms as CT angiography with an AUC (alternative free-response ROC model) of 0.91 compared to DSA \[[@CR74]\] and comparably good at describing aneurysm morphology. Interestingly, computer-aided design can help general radiologists to achieve a high aneurysm detection rate using 3D TOF MRA as shown by Hirai et al. in 2005 \[[@CR75]\]. In summary, non-contrast-enhanced MRI seems to be able to replace contrast-enhanced MRI for untreated aneurysms but not for treated aneurysms.

### Intracranial steno-occlusive carotid disease {#Sec18}

Cerebral perfusion can be assessed using ASL as mentioned previously. Steno-occlusive carotid disease hinders the passage of blood proximal to the occlusion to enter a direct route to the brain. Imaging must be able to depict the cranial perfusion. The severity of symptoms is dependent on the existence of collateral circulation for example via the circle of Willis distal to the occlusion site and can be estimated by territorial ASL and TOF combined with comparable diagnostic quality to DSA \[[@CR76]\] with kappa values of 0.70--0.72. 4D MRA ASL \[[@CR77]\] or TOF alone \[[@CR78]\] can estimate collateral flow in carotid artery steno-occlusive disease in a majority of patients and provide results comparable to DSA with intermodality agreement of kappa = 0.61 \[[@CR77]\]. Since none of the included studies could show an excellent agreement between modalities, probably, non-contrast-enhanced MRI is not able to fully replace contrast-enhanced imaging for intracranial steno-occlusive carotid disease.

### Moyamoya {#Sec19}

Cerebral perfusion in non-atherosclerotic carotid stenosis (moyamoya disease) can be evaluated with ASL \[[@CR79]--[@CR82]\]. Specifically, ASL angiography can visualize cerebral vessels and moyamoya vessels in non-operated hemispheres and stage moyamoya with an accuracy of 86--100% compared to DSA \[[@CR79]\]. ASL can identify changes in CBF in patients with moyamoya disease treated after revascularization (kappa = 0.77 for collateral grading compared with DSA), but does not allow for reliable anastomosis patency (kappa = 0.57), which is better appreciated by DSA \[[@CR82]\]. In summary, non-contrast MRI seems to be able to replace contrast-enhanced MRI in the pre-therapeutic stage but not postoperatively.

### Vasculitis {#Sec20}

Imaging in patients with vasculitis must be able to depict direct signs of vasculitis in the affected vessel as well as tissue-based complications of vasculitis such as hemorrhage and stroke. Although contrast-enhanced MRA can show direct signs of cerebral artery vasculitis by contrast enhancement in the vessel wall, notably the American College of Radiology Appropriateness Criteria for cerebrovascular disease show the same diagnostic rating for MRA head without GBCA as for head MRA with GBCA \[[@CR83]\]. Importantly, DSA is still considered the imaging gold standard, and hence, non-contrast MRI seems to only partly be able to replace contrast-enhanced techniques.

### Cerebral venous thrombosis {#Sec21}

Imaging in cerebral venous thrombosis must be able to identify the clot and the lack of flow in the affected venous structure as well as potential parenchymal effects of venous stasis. The clinical presentation of CVT is variable, and thus, pre-imaging clinical suspicion of cerebral venous thrombosis is difficult \[[@CR84]\]. MRI can detect secondary ischemic and hemorrhagic areas as well as localizing and describing the extent of the thrombosis without the use of GBCA through 3DT1 turbo spin echo (sensitivity and specificity 97--100%) and 2D-TOF (sensitivity and specificity 85--93%) \[[@CR85]\]. Previous data show that contrast-enhanced imaging (AUC = 0.99) is superior to non-contrast-enhanced 2D-TOF MR venography (AUC = 0.88--0.89) to detect cerebral venous thrombosis \[[@CR9]\]. This has also been confirmed by one more recent study \[[@CR86]\]. However, in a recent study evaluating non-contrast-enhanced MRI techniques, 3D phase-contrast MR venography shows high diagnostic accuracy (sensitivity 100%, specificity 71%), especially when combining with non-contrast-enhanced CT and conventional non-contrast-enhanced MRI \[[@CR87]\]. Non-contrast-enhanced MRI seems to be able to partly replace contrast-enhanced techniques in cerebral venous thrombosis, especially when combining with non-contrast-enhanced CT.

Table [1](#Tab1){ref-type="table"} summarizes the diagnostic performance in the studies described above. Table 1Diagnostic accuracy measures in non-contrast-enhanced MRI techniques and contrast-enhanced techniques in cerebrovascular diseaseClinical questionDiagnostic performance non-CEDiagnostic performance CE gold standard or DSA gold standardAuthor (year)Detect cerebral venous thrombosisAUC 0.89 (± 0.03 SD) 2D-TOF MR venographyAUC 0.99 CE T1 3D MP-RAGELiang et al. (2001)Detect cerebral venous thrombosis80% sensitivity, 65% specificityCE MRV reference standardBernard (2017)Detect cerebral venous thrombosisAccuracy 92.7% conv non-contrast-enhanced sequencesAccuracy 98.3 CE T1 3D GRESari (2015)Detect cerebral venous thrombosisSensitivity/specificity100%/71% 3D PC-MR venographyDSA gold standardOzturk et al. (2018)Detect intracranial arteriovenous shunting in AVMAUC 0.97 (95% CI 0.90--1.00) CBF ASL/SWIAUC 0.93 (95% CI 0.87--0.97) conv MRI including CE T1 and CE MRA, DSA reference standardHodel et al. (2017)Nidus localization in AVMSensitivity 100% CBF ASLDSA gold standardBlauwblomme et al. (2015)Evaluation of AVM obliterationAUC 0.94 CBF ASLDSA gold standardKodera et al. (2017)Detect arteriovenous shunting and venous drainage in children with AVMSensitivity 100% CBF ASLDSA gold standardNabavizadeh et al. (2014)Identify fistula site and venous drainage in AV fistulaKappa 1.00 four-dimensional MR angiography ASLDSA gold standardIryo et al. (2014)Detect and localize AV fistulaSensitivity 91% (95% CI 69--98) CBF ASLDSA gold standardAmukotuwa et al. (2016)Characterize dural AV fistula: define shunt location/feeding artery/draining vein/Cognard classificationKappa interreader agreement 1.00/0.92/1.00/1.00 flow-tracking cartographyDSA gold standardEdjlali et al. (2014)Detect intracranial aneurysmsAUC 0.91 TOF MRAAUC 0.91 CT angiography/DSA gold standardHiratsuka et al. (2008)Moyamoya Suzuji stageAccuracy \> 86 (0.86--1 range) ASL-4D MRADSA gold standardUchino et al. (2015)Predictor of 24-h DWI lesion in non-reperfused ischemic strokeAUC 0.76 (95% CI 0.63--0.85) CBF ASLAUC 0.79 (95% CI 73--84) Tmax DSCBivard et al. (2014)Detect arterial occlusion in strokeAccuracy TOF MRA 0.89Accuracy CE MRA 0.99Dhundass et al. (2019)*ASL* arterial spin labeling, *AUC* area under curve, *AV* arteriovenous, *AVM* arteriovenous malformation, *CBF* cerebral blood flow, *CE* contrast-enhanced, *conv* conventional, *CT* computed tomography, *DSA* digital subtraction angiography, *DSC* dynamic susceptibility weighted, *DWI* diffusion-weighted imaging, *MRA* magnetic resonance angiography, *MRV* magnetic resonance venography, *PC* phase contrast, *SWI* susceptibility weighted imaging, *TOF* time of flight

Multiple sclerosis {#Sec22}
------------------

Multiple sclerosis is the classical indication to use GBCA in neuroimaging \[[@CR88], [@CR89]\]. Contrast-enhanced MRI decreases time to diagnosis and helps to identify and characterize multiple sclerosis mimics at first clinical presentation \[[@CR90]\]. However, the presumption that all patients with multiple sclerosis should undergo contrast-enhanced MRI has started to change recently. Follow-up imaging of definite disease does not per se require GBCA administration, although GBCA can be used to re-evaluate the original diagnosis or as new baseline before therapeutic changes \[[@CR91]\]. Previous studies showed a modest correlation between contrast enhancement and clinical outcome \[[@CR92]\]. For example, the relapse rate is not influenced by MRI enhancement status when taking other covariates into account such as disease duration \[[@CR92]\] and the relapse is not predicted by the presence of gadolinium-enhancing lesions on MRI \[[@CR93]\].

Furthermore, several studies have been able to predict contrast enhancement by analysis of non-contrast-enhanced T1- and T2-weighted images MRI \[[@CR94], [@CR95]\] with an AUC of 0.72--0.83, by quantification of fractional anisotropy from diffusion tensor imaging \[[@CR96]\] with an AUC of 0.93, and by texture analysis of T2-weighted images \[[@CR97]\]. Magnetization transfer ratio quantification can also differentiate between contrast-enhancing and non-contrast-enhancing lesions in patients with multiple sclerosis, likely representing the affection of the disease on the BBB integrity \[[@CR98]\].

Non-contrast-enhanced MRI of T2 lesion load and cerebral atrophy show a strong correlation (*R*^2^ = 0.74) with clinical status \[[@CR99]\], and T2 lesion volume only has a moderate correlation with clinical disability at long term follow-up \[[@CR100]\]. Newer volumetric quantitative techniques have shown promise in assessing radiological disease status \[[@CR101]\], but they still lack clear correlation to the clinical status of the patients. It can also be noted that patients presenting with multiple sclerosis are relatively young and subject to repeated examinations, which strengthens the case for reducing the use of GBCA in this patient group. Non-contrast-enhanced MRI seems to be able to replace contrast-enhanced MRI for longitudinal follow-up of patients but not at first presentation. Table [2](#Tab2){ref-type="table"} summarizes the diagnostic performance in the studies described above. Table 2Diagnostic accuracy measures in non-contrast-enhanced MRI techniques and contrast-enhanced techniques in multiple sclerosisClinical questionDiagnostic performance non-CEDiagnostic performance CE gold standardAuthor (year)Predict contrast enhancement in multiple sclerosisAUC 0.83 (95% CI 0.80--0.87) non-enhanced conv MRI and logistic regression model fittingCE T1 reference standardShinohara et al. (2012)Predict contrast enhancement in multiple sclerosisAUC 0.72 T2 burden of diseaseCE T1 reference standardBarkhof et al. (2005)Predict contrast enhancement in multiple sclerosisAUC 0.93 (95% CI 0.87--0.99) T2W, SDC, QSMCE T1 reference standardGupta et al. (2018)Predict contrast enhancement in multiple sclerosisT2-weighted texture parameters 86% sensitivity, 84% specificityCE T1 reference standardMichoux et al. (2015)*AUC* area under curve, CE contrast-enhanced, *conv* conventional, *GBCA* gadolinium-based contrast agent, *SDC* statistical detection of change, *QSM* quantitative susceptibility mapping

Primary and secondary brain tumor {#Sec23}
---------------------------------

### Tumor extent and detection {#Sec24}

Brain tumor detection and characterization is an area where contrast-enhanced MRI is frequently used \[[@CR102], [@CR103]\]. However, since these first report on the application of contrast-enhanced MRI, techniques for non-contrast-enhanced MRI have evolved. As tumor localization and extent are two essential issues in pre-operative brain tumor imaging, non-contrast-enhanced MRI should be able to detect and localize primary brain tumors. This can be achieved by for example T2 FLAIR imaging showing high signal intensity in low-grade gliomas \[[@CR104]\]. In high-grade gliomas, increased signal on T2 FLAIR can encompass tumor edema with tumor cells \[[@CR105]\]. Imaging-histology correlation data show that primary malignant brain tumors rarely have surrounding edema without interspersed tumor cells outside the contrast-enhanced area \[[@CR20]\]. Compared to contrast-enhanced MRI, diffusion imaging can better depict the perifocal tumor density and effects on surrounding white matter tracts \[[@CR106], [@CR107]\]. Further issues in brain tumor imaging relate to the characterization of tumor type and malignancy grade. It is known that the contrast enhancement is an imperfect marker of malignancy grade \[[@CR15]\]. In comparison to primary brain tumors, cerebral metastases can be multiple and small with potential increased lesion detection rate by the use of GBCAs \[[@CR108]\].

Although it may be feasible to exclude the use of GBCA without limiting the ability to detect primary brain tumors, imaging of secondary brain tumors cannot be performed without GBCA. One study reported that 20% of cerebral metastasis were undetected on pre-contrast echo-planar imaging FLAIR \[[@CR109]\]. The use of contrast-enhanced T2 FLAIR has shown higher sensitivity (100%) compared with early phase 3DT1 GRE (76%) \[[@CR110]\]. Contrast-enhanced MRI is compulsory for the detection of small metastases. However, even though GBCA is used (contrast-enhanced T1), leptomeningeal metastasis confirmed by cerebrospinal fluid analysis may not be detected \[[@CR111]\]. In summary, non-contrast-enhanced MRI seems not to be able to replace contrast-enhanced MRI in patients with metastatic disease.

### Differentiation of brain tumors {#Sec25}

A few recent studies demonstrated that support vector machine-based classifiers using histogram features of the ADC from diffusion MRI (AUC = 0.97) could better discriminate between different types of posterior fossa tumors in children than contrast-enhanced T1 or T2 images (AUC = 0.84) \[[@CR112]\]. Texture features from conventional non-contrast-enhanced MRI showed sufficient accuracy to separate childhood tumors into the correct classes (accuracy 71--92%), which is higher than the clinical radiological reading of the cases (47% correct diagnosis) \[[@CR113]\].

Non-contrast-enhanced MRI can also differentiate between cerebral lymphoma and GBM by the use of ADC \[[@CR114]\] with an AUC of 0.94. This can also be achieved by ASL \[[@CR115]\] with an AUC of 0.91 and an accuracy of 95%. MRS can discriminate between metastases and CNS lymphoma/GBM with equal diagnostic performance (AUC = 0.96) as perfusion MRI with contrast agent injection (AUC = 0.97) \[[@CR116]\]. Further, ASL \[[@CR117]\], T2 relaxometry \[[@CR118]\], DKI \[[@CR119]\], and APTw imaging \[[@CR18]\] can discriminate between cerebral metastasis and GBM with sufficient diagnostic performance (AUC = 0.84, 0.86, 1.00, and 0.91, respectively). Aiming to increase the specificity of contrast-enhanced imaging, one can use perfusion weighting such as dynamic susceptibility contrast MRI. This will allow discrimination between glioblastoma, metastasis, and primary central nervous system lymphoma with accuracy between 0.94 and 0.99 \[[@CR120]\].

### Tumor grade discrimination {#Sec26}

High-grade primary brain tumors are not always contrast enhancing. In fact, up to 18% of high-grade gliomas can be non-enhancing \[[@CR15]\]. Magnetic resonance spectroscopy (MRS) (AUC 0.90) and APTw (AUC = 0.82) have shown higher diagnostic performance to grade brain tumors in low- or high-grade, than conventional MRI including contrast-enhanced T1-weighted images (AUC = 0.65) \[[@CR121]\]. One meta-analysis pooling 83 articles showed the value of using Cho/Cr and Cho/NAA as well as contrast-enhanced dynamic perfusion-weighted imaging to differentiate between high-grade and low-grade gliomas \[[@CR122]\]. APTw imaging has shown comparable discriminatory potential to DSC MRI between low- and high-grade brain tumors \[[@CR123]\] with an AUC of 0.85--0.86 for ASL compared to 0.80--0.82 for DSC. Further, both ASL \[[@CR10]\], DKI \[[@CR124]\], and intravoxel incoherent motion imaging \[[@CR125]\] can discriminate between low- and high-grade gliomas (AUC = 0.93-0.96).

### Follow-up after treatment {#Sec27}

In the follow-up of patients treated with surgery and/or radiochemotherapy for brain tumor, the updated Response Assessment in Neuro-Oncology criteria (RANO) consider not only contrast enhancement but also progression of T2 FLAIR changes \[[@CR17], [@CR126]\].

Pseudoprogression and pseudoresponse are two entities that are challenging for the neuroradiologist when evaluating post-therapeutic intracranial tumors on contrast-enhanced MRI \[[@CR17], [@CR126]\]. Non-contrast-enhanced MRI that has shown promise in depicting and discriminating between treatment-related changes and tumor progression includes ASL (AUC = 0.84) \[[@CR27]\], APTw \[[@CR127], [@CR128]\], intravoxel incoherent motion imaging (AUC = 0.94-0.95) \[[@CR37]\], diffusion tensor imaging (AUC = 0.84) \[[@CR129]\], and MRS (AUC = 0.91) \[[@CR130]\]. One recent study showed how quantitative T1 mapping (without GBCA) could be used to monitor GBM during bevacizumab treatment \[[@CR131]\]. Another study utilizing non-contrast-enhanced texture analysis showed high diagnostic performance to differentiate between recurrent tumor and treatment-related changes \[[@CR132]\] with an AUC of 0.79 compared to 0.57 for contrast-enhanced T1-weighted imaging. MRS has shown promise in discriminating between tumor recurrence and treatment-related changes by measuring elevated choline \[[@CR133]--[@CR136]\]. More surprisingly, in patients with diffuse intrinsic pontine glioma, ASL post-radiotherapy shows high CBF in patients with pseudoprogression \[[@CR137]\]. Identifying signs of pseudoprogression is of importance since the misinterpretation of contrast-enhancement as a progressive disease might lead to discontinuation of therapy \[[@CR17]\]. Notably, the use of GBCA in the follow-up of initially non-contrast-enhanced tumors or tumors that lack known potential to malignify can be questioned. The specificity of contrast-enhanced imaging can be increased by perfusion weighting such as dynamic susceptibility contrast MRI. A meta-analysis from 2018 showed a sensitivity of 82% and a specificity of 95% to discriminate between true progression and pseudoprogression by DSC \[[@CR138]\]. In summary, non-contrast-enhanced MRI seems to at least in part be able to replace contrast-enhanced MRI techniques in the diagnosis and follow-up of primary brain tumors.

Table [3](#Tab3){ref-type="table"} summarizes the above-described diagnostic performance. Table 3Diagnostic accuracy measures in non-contrast-enhanced MRI techniques and contrast-enhanced techniques in brain tumor imagingClinical questionDiagnostic performance non-CEDiagnostic performance CE gold standardAuthor (year)Astrocytic tumor gradingAUC 0.96 (95% CI 0.84--1.0) CBF ASLAUC 0.98 (95% CI 0.87--1.00) CBF DSCMorana et al. (2018)Glioma gradingAUC 0.82 (95% CI 0.62--1.00) APTw mean, AUC 0.90 (95% CI 0.73--1.00) Cho/Cr MRSAUC 0.65 (0.47--0.84) CE T1Sakata et al. (2017)Glioma gradingAUC 0.85--0.86 (95% CI 0.74--0.92 and 95% CI 0.75--0.94) APTw90AUC 0.80--0.82 (95% CI 0.64--0.89 and 0.67--0.90) nCBV90 DSCPark et al. (2015)Pediatric posterior fossa gradingAUC 0.97 ADC (classification rate) DWIAUC 0.84 CE T1 (classification rate)Rodriguéz Gutierrez et al. (2014)Discriminate between CNS lymphoma and GBMAUC 0.94 ADC DWIEqual rate of CE T1 contrast enhancement between groupsKo et al. (2016)Discriminate between CNS lymphoma and GBMAccuracy 0.91 (95% CI 0.84--0.95) CBF ASLAccuracy 93--95% conv MRI including CE T1You et al. (2018)Discriminate between metastases and CNS lymphoma/GBMAUC 0.96 Lac/Cr MRSAUC 0.97 PSRmax DSCVallée et al. (2018)Progression vs pseudoprogression in GBMAUC 0.84 (95% CI 0.72--0.96) linear anisotropy DTIAUC 0.77 (95% CI 0.63--0.92) rCBVmax DSCWang et al. (2016)Progression vs pseudoprogression in glial tumors and brain metastasesAUC 0.79 (95% CI 0.77--0.81) T2FLAIRAUC 0.57 (± 0.08) CE T1Tiwari et al. (2016)Progression vs pseudoprogression in gliomaAUC 0.82 CBF ASLAUC 0.84 nrCBV DSCWang et al. (2018)Progression vs pseudoprogression in metastasesAUC 0.94-0.95 (95% CI 0.87--0.98 and 0.88-0.98) IVIMAUC 0.91--0.93 (95% CI 0.83--0.96 and 0.86--0.98) DSC + DWIKim et al. (2014)Progression vs pseudoprogression in GBMAUC 0.89 APTw90AUC 0.77 and 0.80 CBV DSCPark et al. (2016)Detection of cerebral metastasisSensitivity 0.80% FLAIR-EPISensitivity 100% SE-T1WTomura et al. (2007)*ADC* apparent diffusion coefficient, *ASL* arterial spin labeling, *AUC* area under curve, *CBF* cerebral blood flow, *CE* contrast-enhanced, *CNS* central nervous system, *conv* conventional, *DSC* dynamic susceptibility weighted, *DTI* diffusion tensor imaging, *DWI* diffusion-weighted imaging, *FLAIR* fluid attenuated inversion recovery, *GBM* glioblastoma, *IVIM* intravoxel incoherent motion, *MRS* magnetic resonance spectroscopy, *nrCBV* normalized relative cerebral blood volume, *PSR* percentage of signal recovery, *rCBVmax* maximum relative cerebral blood volume

Cerebral abscess and infectious meningitis {#Sec28}
------------------------------------------

Intracranial and cerebral infections are classical indications for contrast-enhanced MRI. However, abscesses and necrotic tumors can have the same appearance and present as ring-enhancing lesions on contrast-enhanced T1-weighted images \[[@CR139]\]. Hence, the exclusive use of contrast-enhanced T1 sequences or contrast-enhanced CT will not help in determining the etiology of the lesion. However, bacterial cerebral abscess can be differentiated from a necrotic or cystic brain tumor by DWI (AUC = 0.96) \[[@CR140]\] with higher diagnostic performance than morphological T1 and T2 images; this has also been reported by other groups \[[@CR139]\] (AUC for DWI = 1.00) as shown in Table [4](#Tab4){ref-type="table"}. DWI has replaced MRS as the method of choice for differentiating between abscesses and necrotic tumors such as glioblastomas and metastases. However, the use of DWI in more uncommon non-pyogenic abscesses is less valid and unable to correctly classify the lesion. Table 4Diagnostic accuracy measures in non-contrast-enhanced MRI techniques and contrast-enhanced techniques in brain infectionClinical questionDiagnostic performance non-CEDiagnostic performance CE gold standardAuthor (year)Abscess detectionSpecificity 100% ADCCE T1 and T2 signal intensity could not distinguish between groupsNadal et al. (2003)Detecting infectious meningitisSensitivity 33% T2 FLAIRSensitivity 100% T2 FLAIRSplendiani et al. (2005)Detecting infectious meningitisSensitivity 25% 3DT2FLAIRSensitivity 75% CE 3DT2FLAIRFukuoka et al. (2010)*ADC* apparent diffusion coefficient, *AUC* area under curve, *CE* contrast-enhanced, *FLAIR* fluid attenuated inversion recovery

Although historically not considered a radiological diagnosis, detection of meningitis has shown higher sensitivity on contrast-enhanced T2 FLAIR images (100% sensitivity) compared to non-contrast-enhanced T2 FLAIR (33% sensitivity) or contrast-enhanced T1 (50% sensitivity) \[[@CR141]\]. Another study showed a higher sensitivity to detect meningitis by contrast-enhanced T2 FLAIR (75% sensitivity) compared to non-contrast-enhanced 3DT2FLAIR (25% sensitivity) \[[@CR142]\]. In ventricular infection, DWI can assess the presence of intraventricular pus \[[@CR86], [@CR143]\]. Except for meningitis, non-contrast-enhanced MRI using DWI seems to be able to replace contrast-enhanced MRI for the detection of cerebral abscess. In fact, for abscess detection, DWI seems superior to contrast-enhanced techniques.

Discussion {#Sec29}
==========

In this review, we have summarized data on how non-contrast-enhanced MRI can detect and characterize pathology in, at least, ten specific diseases with a diagnostic performance comparable with contrast-enhanced MRI for specific clinical questions. Although we agree that GBCA can increase lesion detection (sensitivity), the specificity in lesion characterization by contrast-enhanced MRI is often low compared to other more advanced MR sequences. In fact, the high sensitivity and the low specificity can mislead clinical decisions \[[@CR15]--[@CR20]\]. Contrast agent injection---to achieve a high lesion-to-background contrast---is relatively less important in MRI compared to CT with inherent much higher soft tissue contrast.

In general, the data summarized in this review showed the lowest diagnostic performance for static GBCA MRI such as contrast-enhanced T1 but higher performance for dynamic GBCA MRI such as DSC perfusion. This highlights the importance of depicting physiological properties of GBCA injection such as perfusion of the tissue to increase diagnostic accuracy in clinical practice.

Although new clinical guidelines \[[@CR5], [@CR144]--[@CR148]\] increase the awareness of GBCA usage, we believe there is still a long way to go before GBCA can be fully replaced by other imaging techniques. In fact, there are many diseases and situations where an MRI scan cannot be reliably assessed based on non-contrast-enhanced imaging alone. Examples based on this review are detection of meningitis, cerebral metastasis, and dural sinus venous thrombosis. The main reason to use GBCA is to increase the sensitivity in detecting a disease, since a missed disease can lead to the wrong or no treatment. Furthermore, this review predominately included articles focused on specific sequences and not full clinical protocols. Even though specific non-contrast-enhanced sequences were found to have the capacity to aid clinical diagnosis, in reality, a routine clinical MRI protocol includes several imaging sequences and contrast-enhanced imaging is still one important part. We also have to be aware that first reports on new techniques are often more positive than later published studies \[[@CR149]\] and that these new techniques have downsides such as prolonged scan time, motion sensitivity, and lack of availability. In patients with short estimated survival, the potential long-term risk of GBCA can be overlooked. The use of GBCA might be more important in primary brain imaging at first clinical presentation and less needed for follow-up scanning especially when dealing with children that get repeated scanning at young age or patients with chronic diseases like multiple sclerosis. Clinical examples where non-contrast-enhanced MRI can be used instead of contrast-enhanced MRI already today are in the evaluation of, for example, dural sinus venous thrombosis in pregnant women \[[@CR150]\]. Other clinical examples include patients with intracranial pathology that also have kidney failure or in premature infants.

This review highlights that non-contrast-enhanced MRI techniques can be used in several diseases affecting the brain, but many diseases have not been covered in this review. In addition, there are few published studies focusing on the comparison of non-contrast-enhanced and contrast-enhanced MRI and there is still a lack of evidence to include or exclude GBCAs from clinical routine protocols for many diseases.

We suggest that to further evaluate the use of GBCA in routine clinical protocols for different brain disease, single or multicenter studies should be performed evaluating a random sample of neuroimaging cases investigated with both non-contrast-enhanced and contrast-enhanced MRI. Multiple independent reviewers should be used to further clarify when GBCA is most valuable with regard to the level of clinical confidence for diagnosing and characterizing lesions.

Further, the cost benefit and patient benefit must be considered when deciding on protocol optimization as well as the potential associated risks. There are several advantages when not injecting GBCA, for example, lower the indication for an intravenous line which facilitates the logistics for the patients with no need for serum creatinine blood sample before MRI scanning, reduced cost of contrast media, reduced preparation time for scanning, and reduced risk of adverse events.

One last caveat is how imaging really affects the outcome of the patients. In general, there is a shortage of radiological studies validating their findings towards defined clinical endpoints such as symptoms or survival. Further studies should direct the attention towards the added benefit for patient outcome using GBCAs.

Conclusion {#Sec30}
==========

This review presents non-contrast-enhanced alternatives in MR neuroimaging for ten specific diseases and describes the advantages and disadvantages of ASL, TOF, phase contrast, DWI, MRS, SWI, and APT imaging together with data on diagnostic performance compared to contrast-enhanced alternatives.

ADC

:   Apparent diffusion coefficient

APTw

:   Amide proton transfer-weighted

ASL

:   Arterial spin labeling

AV

:   Arteriovenous

AVM

:   Arteriovenous malformation

CBF

:   Cerebral blood flow

DCE

:   Dynamic contrast-enhanced

DKI

:   Diffusion kurtosis imaging

DSA

:   Digital subtraction angiography

DSC

:   Dynamic susceptibility contrast

GBCA

:   Gadolinium-based contrast agent

GBM

:   Glioblastoma

IVIM

:   Intravoxel incoherent motion

MRA

:   Magnetic resonance angiography

MRS

:   Magnetic resonance spectroscopy

PC

:   Phase contrast

RF

:   Radio-frequency

TOF

:   Time of flight
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